anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A cosmetic composition is provided to delaminate stratum corneum and to effectively remove blemishes such as freckles, melasma, and age spots. CONSTITUTION: A cosmetic composition for promoting delamination of stratum corneum contains 0.1-20 wt% of a Dictyophora echinovolvata extract as an active ingredient. The extract is prepared from Dictyophora echinovolvata fruit body using water, C1-C3 alcohol, or a mixture thereof. The cosmetic composition is manufactured in the form of a cream, a skin softener, an astringent, a milk lotion, a foundation, a soap, and a cleansing foam. The cosmetic composition further contains keratinase. [Reference numerals] (AA) Keratin exfoliation rate(%); (BB) Alpha hydroxy acid; (CC) Mycelium extract; (DD) Fruit body extract
Presentation features such as spelling, punctuation and handwriting can influence the evaluation of general text quality. High school students with dyslexia might therefore be at a disadvantage, as at least their spelling performance is typically poor(er). Furthermore, these students might show less sophisticated linguistic features of texts, such as word length and sentence complexity, that might also be related to text quality. We compared narratives written by Dutch high school students (mean age 13.7 years) with (n = 28) and without (n = 29) dyslexia. Students with dyslexia's texts contained more spelling errors and poorer handwriting quality, but not more punctuation errors. Teacher-rated general text quality was lower for the texts of students with dyslexia in uncorrected versions. When spelling and punctuation errors were corrected, no teacher-rated text quality differences emerged. No differences in linguistic text features were found. Furthermore, spelling, punctuation and, to a lesser extent, number of words per sentence clause were related to ratings of text quality across participants. These results confirm the influence of presentation features on text quality rating. They encourage teachers to be aware of this effect and emphasize the importance of spelling and writing support and interventions for students with dyslexia throughout education.
The invention relates to a method and a product for cleaning and/or whitening of teeth. In oral hygiene products, cysteine proteinases have been shown to have a cleaning and whitening action on the teeth. However, tissues suffer damage from an extended action of cysteine proteinases. In this invention, natural human cysteine proteinases are employed for cleaning and whitening purposes and this activity can be blocked by natural cysteine proteinase inhibitors, which are released secondarily from the products at a later stage. In particular, the use of natural cysteine proteinases and their inhibitors provides the advantage that they are man's own proteins, and therefore the risk of allergization is minimized. In addition, their enzyme kinetics is presently well known.
Glyburide and metformin hydrochloride tablets, USP for oral use contain glyburide USP and metformin hydrochloride USP. 

Glyburide USP is a sulfonylurea and its chemical name is 1-[[p-[2-(5-chloro-o-anisamido) ethyl]phenyl]sulfonyl]-3-cyclo-hexylurea. Glyburide USP is a white to off-white crystalline compound with molecular formula of C23H28ClN3O5S and a molecular weight of 494.01. The structural formula is represented below.

Metformin hydrochloride USP is a biguanide in hydrochloride salt form and its chemical name is N,N-dimethylimidodicarbonimidic diamide monohydrochloride. It is a white to off-white crystalline compound with molecular formula of C4H12ClN5 (monohydrochloride) and a molecular weight of 165.63. Metformin is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin is 6.68. The structural formula is as shown: 

Glyburide and metformin hydrochloride tablets, USP are available in film-coated containing 1.25 mg glyburide USP with 250 mg metformin hydrochloride USP, 2.5 mg glyburide USP with 500 mg metformin hydrochloride USP, and 5 mg glyburide USP with 500 mg metformin hydrochloride USP. In addition, each film-coated tablet contains the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, hypromellose, propylene glycol, polysorbate 80, talc, titanium dioxide and FD&C Yellow#6 aluminum lake. The 1.25 mg/250 mg and 5 mg/500 mg strengths also contain D&C Yellow#10 aluminum lake; The 2.5 mg/500 mg strength also contains FD&C Red#40 aluminum lake. 

Meets USP Dissolution Test 2
BACKGROUND: Although allergic rhinitis (AR) can negatively impact the ability to smell, the degree to which this occurs is not clear and prevalence estimates vary among studies. This study had 4 main objectives: (1) To estimate the prevalence and the degree of olfactory dysfunction in AR patients; (2) To compare olfactory perception between AR patients with different persistence and severity of symptoms and determine if olfactory testing may aid in differentiating among Allergic Rhinitis and its Impact on Asthma (ARIA) groups; (3) To determine whether allergic reactions to different allergens differentially impact olfactory function, and (4) Verify possible changes in the olfactory epithelium (OE) caused by AR.
METHODS: One hundred thirty-three patients with AR and one hundred controls were tested. The main outcome was the score in University of Pennsylvania Smell Identification Test (UPSIT®). The OE was examined using immunofluorescence markers for neuronal activity, apoptosis, oxidative stress, signal transduction, eosinophils, and epithelial thickness.
RESULTS: Prevalence of olfactory dysfunction in the AR patients was higher (AR: 42.9% vs controls: 9%, P < .001). No difference was found either between intermittent and persistent disease cases (P = .58) or between cases with mild and those with moderate/severe symptomatology (P = .33). Lower olfactory capacity was not associated with the reaction to more (P = .48) or diverse types of allergens (Ps > .05). Although not significant, patients with AR had a greater amount of eosinophilia and a lower amount of cAMP (cyclic adenosine monophosphate) in the OE.
CONCLUSION: The study highlights a higher prevalence of olfactory dysfunction in AR patients compared to controls, but olfactory testing may not effectively differentiate AR severity or allergen sensitivities. Although trends suggest potential pathophysiological changes in the OE of AR patients, further research is needed to validate these findings.
Adults - The usual dose is 30 to 60 mL. Children 14 years of age and over, of average weight, may receive the adult dose. The total dose is normally injected within 30 to 90 seconds. Higher dosage may be indicated to achieve optimum results in instances where poor visualization may be anticipated (e.g., elderly patients or patients with impaired renal function). When nephrograms and/or sequential urograms are desired, the total dose should be rapidly injected, normally within 15 to 30 seconds. 

The dosage for children is reduced in proportion to age and body weight. The following approximate schedule is recommended for infants and children, based on a dosage of about 0.5 mL/kg of body weight:
<P>PROBLEM TO BE SOLVED: To obtain a composition for effectively preventing blood flow deterioration and a food and beverage and a hair grower containing the same.  <P>SOLUTION: The composition having a prevention action on blood flow deterioration comprises one or a plurality of essences selected from soybean, krill and rush and one or a plurality of essences selected from ginkgo leaves and petals of safflower as active ingredients. The composition having a prevention action on blood flow deterioration comprises an essence obtained by fermenting one or a plurality of essences selected from soybean, krill and rush and one or a plurality of essences selected from ginkgo leaves and petals of safflower with Bacillus natto as active ingredients. The food and beverage comprise the composition. The hair grower comprises the composition.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The SHAPES-Captivity study seeks to identify metagenomic components of the intestinal microbiome shared by human beings and captive great apes living in proximity and in direct, daily contact. The SHAPES-Captivity is an extension of the SHAPES study (financed by the ANR in 2014), currently ongoing in central Africa (Democratic Republic of Congo, Cameroon, Gabon). In Cameroon, the investigators have collected stool samples from gorillas, chimpanzees and human beings using the same forest space so as to conduct an analysis of the overlap of their intestinal microbiome. The results of this analysis will be interpreted in light of anthropological and geographical evidence collected among people living in this region. SHAPES-Captivity will enable the investigators to use the same approach but this time, under conditions of great ape captivity. The investigators will thus obtain data concerning intestinal microbiome overlap between captive great apes and human caretakers working in a controlled environment and in daily, direct contact. The SHAPES-Captivity study will provide a positive control, which will eventually be compared to results from the SHAPES study. Although multiple studies have investigated the overlap between human-great ape intestinal microbiome (Moeller et al. 2012 ; Moeller et al. 2016), none of these studies have investigated people living in close proximity to great apes, either in a natural or captive setting. The investigators will determine the phylogenetic diversity of enterotypes (bacterial and viral) shared between human beings and great apes, and will link these results with their participant-observations of caretakers' activities (and contacts) with these great apes.
Participants will receive IV infusion or SC injection of Talquetamab at each putative recommended Phase 2 dose(s) (RP2D\[s\]) as determined in Part 1. All participants (ongoing and those who are in follow-up) will transition to OLE phase and will continue to receive the study treatment.
As with the management of all overdosage, the possibility of multiple drug ingestion should be considered.

When treating overdose, practitioners should bear in mind that there is a prolonged release of dexmethylphenidate from dexmethylphenidate hydrochloride extended-release capsules.

Treatment consists of appropriate supportive measures. The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. Gastric contents may be evacuated by gastric lavage as indicated. Before performing gastric lavage, control agitation and seizures if present and protect the airway. Other measures to detoxify the gut include administration of activated charcoal and a cathartic. Intensive care must be provided to maintain adequate circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia.

Efficacy of peritoneal dialysis for dexmethylphenidate hydrochloride overdosage has not been established.
An anticancer implant is characterized in that active anticancer ingredient is wrapped into pharmaceutical excipient to be made into the sustained-released implant or sustained injection. The active anticancer ingredient is the combination of anti-metabolism anticancer medicine and synergistic agent thereof. The synergistic agent is made from mustine drug and/or antimitotic drug and/or plant alkaloids. The pharmaceutical excipient is made from polylactic acid, copolymer of polyglycolic acid and glycolic acid, ethylene-vinyl acetate copolymer, FAD: sebacic acid (SA) copolymer and/or polifeprosan, etc. The sustained-release injection is composed of sustained release microspheres and menstruum, and the menstruum is classified into common menstruum and special menstruum with suspending agent. The suspending agent is made from sodium carboxymethyl cellulose, mannite, etc. and is used for suspending active anticancer ingredients or sustained-release gains or microspheres containing active anticancer ingredients so as to facilitate injection. Partial tumor placement or sustained-release agent injection can reduce medicine systemic toxicity effect as well as can selectively increase medicine concentration at partial tumor to enhance the curative effect of non-operative treatments such as chemotherapeutic drug, radiation therapy, etc.
FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
FIELD: conservation of velvet antlers of northern deer. SUBSTANCE: velvet antlers ate stepped treated by hot air. The first step takes place within 4 h at 70-72 C, preliminary heating to 68-70 C being carried out. Then wind drying within 48 h takes place. Said cycle is repeated 2-3 times. The second step takes place within 4 h at 65-68 C, stream of hot air being used; velvet antlers are preliminary heated to 65 C. Then wind drying within 48-72 h is carried out. The third step is carried out within 4-10 days with the help of draft till tops of velvet antlers become hard. EFFECT: decreases drying time, improves quality of velvet antlers. 1 tbl
Use of specific proteins, peptides and antibodies to prepare a reagent for detecting and optionally serotyping a coronavirus (CV) associated with severe acute respiratory syndrome (SARS). Use of specific proteins, peptides and antibodies to prepare a reagent for detecting and optionally serotyping a coronavirus (CV) associated with severe acute respiratory syndrome (SARS). The specific reagents are: (a) a protein or peptide (I) encoded by a 29746 base pair (bp) sequence (1), given in the specification; (b) a mono- or poly-clonal antibody (Ab), or its fragment, directed against (I); or (c) a protein/peptide chip or filter that contains (I) or Ab, or its fragments. Independent claims are also included for the following: (1) method for detecting CV by treating a sample with the specified reagents and detecting any antigen-antibody complex formed; (2) a kit for detecting CV that includes any of the specified reagents; (3) an immunogenic composition that contains at least one of (I), specified DNA or RNA sequences (II), a recombinant expression vector that contains (II), or a cDNA bank that contains (II); and (4) immune complexes formed between an isolated protein or peptide and an Ab directed specifically against an epitope of CV. ACTIVITY : Virucide. No details of tests for virucidal activity are given. MECHANISM OF ACTION : Vaccine.
A computer implemented method for recipe and menu creation based upon ingredient information includes receiving, from a menu author, one or more menu configuration parameters and rendering a multi-dimensional grid with cell dimensions corresponding to the one or more menu configuration parameters. Input is received from the menu author, for each cell to the multi-dimensional grid specifying one or more recipes. Each of the recipes comprises at least one ingredient. Each ingredient has an associated ingredient scratch factor corresponding to the ingredient's processing characteristics. For each of the recipes, a recipe scratch factor is calculated based on the associated ingredient scratch factor corresponding to each ingredient in the recipe. A menu scratch factor is calculated by summing the recipe scratch factors, and it is determined whether the menu meets dietary guidelines. If the menu meets the dietary guidelines, the menu is displayed to users.
While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
Behavioral adjustments to mitigate increasing risk of STIs can increase or decrease the likelihood of pregnancy. This paper measures the effects of the arrival and spread of AIDS across U.S. cities in the 1980s and 1990s on births and abortions. I show that the AIDS epidemic increased the birth rate by 0.55 percent and the abortion rate by 1.77 percent. I find support for two underlying mechanisms to explain the increase in pregnancies. Some women opted into monogamous partnerships in response to the AIDS epidemic, with a corresponding increase in the marriage rate and improvement in infant health. Others switched from prescription contraceptive methods to condoms. These behavioral changes lowered the incidence of other sexually transmitted infections, but increased both planned and unplanned pregnancies.
This was a Phase 1, outpatient, open-label, dose-escalating study to evaluate the safety, tolerability, and immunogenicity of 4 doses of the Group B Meningococcal HOPS-G 8570 NOMV vaccine in healthy subjects. Subjects were screened by medical history; physical exam; complete blood count; serum chemistry profile; coagulation studies including prothrombin time (PT), partial thromboplastin time (PTT), and fibrinogen; human immunodeficiency virus (HIV) test, anti-hepatitis C virus (HCV) antibodies, and hepatitis B surface antigen (HBsAg) test results; nasopharyngeal swabs for carriage of meningococci; bactericidal antibody titer to meningococci; and urinalysis; and urine pregnancy test results for females. The first 36 subjects to meet all inclusion criteria and none of the exclusion criteria were assigned to 1 of 4 dosage groups of 9 subjects each. After screening, there was a 10 to 60 day lead-in time (depending on when screening occurred) prior to vaccination during which subjects could not take or receive any experimental products. Also prior to vaccination, adverse events were recorded to establish a baseline with which to compare adverse events occurring after vaccination. Subjects kept a diary for 7 days before the first dose and for 1 day before each of the second and third doses. Immediately before each vaccination, vital signs were checked, an abbreviated physical examination was performed, each subject's throat was swabbed to assess carriage of meningococcal bacteria, and blood was drawn for immunology and safety labs. Urine was collected for analysis and females took a urine pregnancy test. The pregnancy test results had to be negative in order for a subject to be vaccinated. The vaccine with adjuvant was given intramuscularly at 0, 6, and 12 weeks (Study Days 0, 42, and 84) in doses of 10 μg, 25 μg, 50 μg, or 75 μg based on protein concentration. Vaccinations were performed in a staggered fashion with safety monitoring between groups. The 10-μg dose group was divided into 2 subgroups. Subjects in the first subgroup were vaccinated 30 minutes apart to observe subjects for the occurrence of acute side effects, and subjects in the second subgroup were vaccinated 1 week after the first. The subjects in each group were monitored for AE for at least 2 weeks prior to vaccinating the next higher dosage group. Subjects were kept in the Clinical Trials Center for 30 minutes after each vaccination for observation, and they were asked to keep a diary of symptoms for 7 days after each vaccination. AEs and SAEs were recorded at all study visits, and each AE or SAE was assessed for severity and relationship to the vaccine by the investigator.
Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
There remains a high incidence of blood transfusion in patients following hip fractures. Tranexamic acid (TXA) has well-studied efficacy in decreasing blood loss and transfusion requirements in the context of general trauma, as well as several elective orthopaedic procedures. Although blood is lost in hip fracture surgery itself, it is also known that there is significant blood loss pre-operatively following the hip fracture event, particularly in extracapsular hip fractures. A prospective, randomized, double blinded, placebo controlled trial will elucidate the roll of early administration of TXA in a population of patients who sustain hip fractures. The study aims to investigate the hypothesis that early administration of TXA following diagnosis of hip fracture will lower pre and postoperative blood loss and transfusion rates. There will be two treatment arms in the study. The treatment group will be given 1950mg of oral TXA (3 tablets, 650mg each) in the emergency department following diagnosis of hip fracture. Those randomized to the control group will be given 3 tablets of oral placebo in the emergency department following diagnosis of hip fracture. Patients will then be admitted to the Orthopaedic Trauma service and treated surgically with cephalomedullary nail, hemiarthroplasty, sliding hip screw, percutaneous screws, or total hip arthroplasty.
This disclosure relates to polypeptides that may be used as immunogens in immunogenic compositions (e.g., vaccines) for eliciting an immune response in a subject against staphylococci (such as coagulase-negative staphylococci (CoNS) and/or  S. aureus  species). The immune response elicited (e.g., antibodies) inhibits biofilm development and may be sufficient for treating and/or preventing disease resulting from an infection by a  Staphylococcus  species. Binding agents that bind to these polypeptides are also provided. Exemplary polypeptides include but are not limited to SEQ ID NOs: 1-38 and fragments and derivatives thereof. Immunogenic compositions including one or more polypeptides are provided, as are methods for their use (e.g., to induce an immune response to staphylococci in a subject by administering to the subject a composition as described herein). Administration of the compositions of the present disclosure to a subject may elicit an immune response against a number of  Staphylococcus  species and/or strains.
The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
Patients with past history of TBI will perform a 12 weeks program: intermittent hypobaric hypoxia (IHH) 2 hours at a simulated altitude of 4500 meters 3 days/week. Muscle electro-stimulation for two periods of 20 minutes during the stay in the hypobaric chamber.